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MD, PhDSection 1: Introduction
During the past three decades, catheter and surgical ablation of
atrial ﬁbrillation (AF) have evolved from investigational proce-
dures to their current role as effective treatment options for
patients with AF. Surgical ablation of AF, using either standard,
minimally invasive, or hybrid techniques, is available in most
major hospitals throughout the world. Catheter ablation of AF is
even more widely available, and is now the most commonly per-
formed catheter ablation procedure.
In 2007, an initial Consensus Statement on Catheter and Sur-
gical AF Ablation was developed as a joint effort of the Heart
Rhythm Society (HRS), the European Heart Rhythm Association
(EHRA), and the European Cardiac Arrhythmia Society (ECAS).1
The 2007 document was also developed in collaboration with the
Society of Thoracic Surgeons (STS) and the American College of
Cardiology (ACC). This Consensus Statement on Catheter and
Surgical AF Ablation was rewritten in 2012 to reﬂect the many
advances in AF ablation that had occurred in the interim.2 The rateTable 1
Atrial ﬁbrillation deﬁnitions
AF episode An AF episode is deﬁned as AF that is documented by ECG
30 seconds, or if less than 30 seconds, is present throug
requires that sinus rhythm be documented by ECG mon
Chronic AF Chronic AF has variable deﬁnitions and should not be u
Early persistent AF Early persistent AF is deﬁned as AF that is sustained be
Lone AF Lone AF is a historical descriptor that is potentially con
undergoing AF ablation.
Long-standing persistent AF Long-standing persistent AF is deﬁned as continuous AF
Paroxysmal AF Paroxysmal AF is deﬁned as AF that terminates spontan
Permanent AF Permanent AF is deﬁned as the presence of AF that is ac
or maintain sinus rhythm will be undertaken. The term
physician rather than an inherent pathophysiological at
rhythm control strategy with antiarrhythmic drug thera
Persistent AF Persistent AF is deﬁned as continuous AF that is sustain
Silent AF Silent AF is deﬁned as asymptomatic AF diagnosed with
AF ¼ atrial ﬁbrillation; ECG ¼ electrocardiogram.of advancement in the tools, techniques, and outcomes of AF
ablation continue to increase as enormous research efforts are
focused on the mechanisms, outcomes, and treatment of AF. For
this reason, the HRS initiated an effort to rewrite and update this
Consensus Statement. Reﬂecting both the worldwide importance
of AF, as well as the worldwide performance of AF ablation, this
document is the result of a joint partnership between the HRS,
EHRA, ECAS, the Asia Paciﬁc Heart Rhythm Society (APHRS), and
the Latin American Society of Cardiac Stimulation and Electro-
physiology (Sociedad Latinoamericana de Estimulación Cardíaca y
Electroﬁsiología [SOLAECE]). The purpose of this 2017 Consensus
Statement is to provide a state-of-the-art review of the ﬁeld of
catheter and surgical ablation of AF and to report the ﬁndings of a
writing group, convened by these ﬁve international societies. The
writing group is charged with deﬁning the indications, techniques,
and outcomes of AF ablation procedures. Included within this
document are recommendations pertinent to the design of clinical
trials in the ﬁeld of AF ablation and the reporting of outcomes,
including deﬁnitions relevant to this topic.
The writing group is composed of 60 experts representing 11
organizations: HRS, EHRA, ECAS, APHRS, SOLAECE, STS, ACC,
American Heart Association (AHA), Canadian Heart Rhythm
Society (CHRS), Japanese Heart Rhythm Society (JHRS), and Bra-
zilian Society of Cardiac Arrhythmias (Sociedade Brasileira de
Arritmias Cardíacas [SOBRAC]). All the members of the writing
group, as well as peer reviewers of the document, have provided
disclosure statements for all relationships that might be perceivedmonitoring or intracardiac electrogrammonitoring and has a duration of at least
hout the ECG monitoring tracing. The presence of subsequent episodes of AF
itoring between AF episodes.
sed to describe populations of AF patients undergoing AF ablation.
yond 7 days but is less than 3 months in duration.
fusing and should not be used to describe populations of patients with AF
of greater than 12 months’ duration.
eously or with intervention within 7 days of onset.
cepted by the patient and physician, and for which no further attempts to restore
permanent AF represents a therapeutic attitude on the part of the patient and
tribute of AF. The term permanent AF should not be used within the context of a
py or AF ablation.
ed beyond 7 days.
an opportune ECG or rhythm strip.
Figure1. Anatomical drawings of the heart relevant to AF ablation. This series of drawings shows the heart and associated relevant structures from four different per-
spectives relevant to AF ablation. This drawing includes the phrenic nerves and the esophagus. A: The heart viewed from the anterior perspective. B: The heart viewed from
the right lateral perspective. C: The heart viewed from the left lateral perspective. D: The heart viewed from the posterior perspective. E: The left atrium viewed from the
posterior perspective.
Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
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In writing a consensus document, it is recognized that con-
sensus does not mean that there was complete agreement among
all the writing group members. Surveys of the entire writing group
were used to identify areas of consensus concerning performance
of AF ablation procedures and to develop recommendations con-
cerning the indications for catheter and surgical AF ablation. These
recommendations were systematically balloted by the 60 writing
group members and were approved by a minimum of 80% of these
members. The recommendations were also subject to a 1-month
public comment period. Each partnering and collaborating orga-
nization then ofﬁcially reviewed, commented on, edited, and
endorsed the ﬁnal document and recommendations.
The grading system for indication of class of evidence level was
adapted based on that used by the ACC and the AHA.3,4 It is
important to state, however, that this document is not a guideline.
The indications for catheter and surgical ablation of AF, as well asrecommendations for procedure performance, are presented with
a Class and Level of Evidence (LOE) to be consistent with what the
reader is familiar with seeing in guideline statements. A Class I
recommendation means that the beneﬁts of the AF ablation pro-
cedure markedly exceed the risks, and that AF ablation should be
performed; a Class IIa recommendation means that the beneﬁts of
an AF ablation procedure exceed the risks, and that it is reasonable
to perform AF ablation; a Class IIb recommendation means that
the beneﬁt of AF ablation is greater or equal to the risks, and that
AF ablation may be considered; and a Class III recommendation
means that AF ablation is of no proven beneﬁt and is not
recommended.
The writing group reviewed and ranked evidence supporting
current recommendations with the weight of evidence ranked as
Level A if the data were derived from high-quality evidence from
more than one randomized clinical trial, meta-analyses of high-
quality randomized clinical trials, or one or more randomized
clinical trials corroborated by high-quality registry studies. The
writing group ranked available evidence as Level B-R when there
Figure 2. This ﬁgure includes six CT or MR images of the left atrium and pulmonary veins viewed from the posterior perspective. Common and uncommon variations in PV
anatomy are shown. A: Standard PV anatomy with 4 distinct PV ostia. B: Variant PV anatomy with a right common and a left common PV. C: Variant PV anatomy with a left
common PV with a short trunk and an anomolous PV arising from the right posterior left atrial wall. D and E: Variant PV anatomy with a common left PV with a long trunk.
F: Variant PV anatomy with a massive left common PV.
Figure 3. Schematic drawing showing various hypotheses and proposals concerning the mechanisms of atrial ﬁbrillation. A: Multiple wavelets hypothesis. B: Rapidly
discharging automatic foci. C: Single reentrant circuit with ﬁbrillatory conduction. D: Functional reentry resulting from rotors or spiral waves. E: AF maintenance resulting
from dissociation between epicardial and endocardial layers, with mutual interaction producing multiplying activity that maintains the arrhythmia.
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Figure 4. Structure and mechanisms of atrial ﬁbrillation. A: Schematic drawing of the left and right atria as viewed from the posterior perspective. The extension of muscular
ﬁbers onto the PVs can be appreciated. Shown in yellow are the ﬁve major left atrial autonomic ganglionic plexi (GP) and axons (superior left GP, inferior left GP, anterior
right GP, inferior right GP, and ligament of Marshall). Shown in blue is the coronary sinus, which is enveloped by muscular ﬁbers that have connections to the atria. Also
shown in blue is the vein and ligament of Marshall, which travels from the coronary sinus to the region between the left superior PV and the left atrial appendage. B: The
large and small reentrant wavelets that play a role in initiating and sustaining AF. C: The common locations of PV (red) and also the common sites of origin of non-PV triggers
(shown in green). D: Composite of the anatomic and arrhythmic mechanisms of AF.
Adapted with permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
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clinical trials, or meta-analyses of moderate-quality randomized
clinical trials. Level B-NR was used to denote moderate-quality
evidence from one or more well-designed, well-executed non-
randomized studies, observational studies, or registry studies. This
designation was also used to denote moderate-quality evidence
from meta-analyses of such studies. Evidence was ranked as Level
C-LD when the primary source of the recommendation was ran-
domized or nonrandomized observational or registry studies with
limitations of design or execution, meta-analyses of such studies,
or physiological or mechanistic studies of human subjects. Level C-
EO was deﬁned as expert opinion based on the clinical experience
of the writing group.
Despite a large number of authors, the participation of several
societies and professional organizations, and the attempts of the
group to reﬂect the current knowledge in the ﬁeld adequately, this
document is not intended as a guideline. Rather, the group would
like to refer to the current guidelines on AF management for the
purpose of guiding overall AF management strategies.5,6 This
consensus document is speciﬁcally focused on catheter and sur-
gical ablation of AF, and summarizes the opinion of the writing
group members based on an extensive literature review as well as
their own experience. It is directed to all health care professionals
who are involved in the care of patients with AF, particularly those
who are caring for patients who are undergoing, or are being
considered for, catheter or surgical ablation procedures for AF, and
those involved in research in the ﬁeld of AF ablation. This state-
ment is not intended to recommend or promote catheter orsurgical ablation of AF. Rather, the ultimate judgment regarding
care of a particular patient must be made by the health care
provider and the patient in light of all the circumstances presented
by that patient.
The main objective of this document is to improve patient care
by providing a foundation of knowledge for those involved with
catheter ablation of AF. A second major objective is to provide
recommendations for designing clinical trials and reporting out-
comes of clinical trials of AF ablation. It is recognized that this ﬁeld
continues to evolve rapidly. As this document was being prepared,
further clinical trials of catheter and surgical ablation of AF were
under way.Section 2: Deﬁnitions, Mechanisms, and Rationale for AF
Ablation
This section of the document provides deﬁnitions for use in the
diagnosis of AF. This section also provides an in-depth review of
the mechanisms of AF and rationale for catheter and surgical AF
ablation (Table 1, Figures 16).Section 3: Modiﬁable Risk Factors for AF and Impact on
Ablation
Management of patients with AF has traditionally consisted of
three main components: (1) anticoagulation for stroke prevention;
Figure 5. Schematic drawing showing mechanisms of atrial ﬂutter and atrial tachycardia. A: Isthmus-dependent reverse common (clockwise) atrial ﬂutter. B: Isthmus-
dependent common (counter clockwise) atrial ﬂutter. C: Focal atrial tachycardia with circumferential spread of activation of the atria (can arise frommultiple sites within the
left and right atrium). D: Microreentrant atrial tachycardia with circumferential spread of activation of the atria. E: Perimitral atrial ﬂutter. F: Roof-dependent atrial ﬂutter.
H. Calkins et al. / Journal of Arrhythmia 33 (2017) 369–409 375(2) rate control; and (3) rhythm control. With the emergence of
large amounts of data, which have both deﬁned and called
attention to the interaction between modiﬁable risk factors and
the development of AF and outcomes of AF management, we
believe it is time to include risk factor modiﬁcation as the fourth
pillar of AF management. This section of the document reviews the
link between modiﬁable risk factors and both the development of
AF and their impacts on the outcomes of AF ablation.Section 4: Indications
Shown in Table 2, and summarized in Figures 7 and 8 of this
document, are the Consensus Indications for Catheter and Surgical
Ablation of AF. As outlined in the introduction section of this
document, these indications are stratiﬁed as Class I, Class IIa, Class
IIb, and Class III indications. The evidence supporting these indi-
cations is provided, as well as a selection of the key references
supporting these levels of evidence. In making these recommen-
dations, the writing group considered the body of published lit-
erature that has deﬁned the safety and efﬁcacy of catheter and
surgical ablation of AF. Also considered in these recommendations
is the personal lifetime experience in the ﬁeld of each of the
writing group members. Both the number of clinical trials and the
quality of these trials were considered. In considering the class of
indications recommended by this writing group, it is important to
keep several points in mind. First, these classes of indications only
deﬁne the indications for catheter and surgical ablation of AF
when performed by an electrophysiologist or a surgeon who has
received appropriate training and/or who has a certain level of
experience and is performing the procedure in an experienced
center (Section 11). Catheter and surgical ablation of AF are highly
complex procedures, and a careful assessment of the beneﬁt and
risk must be considered for each patient. Second, these indicationsstratify patients based only on the type of AF and whether the
procedure is being performed prior to or following a trial of one or
more Class I or III antiarrhythmic medications. This document for
the ﬁrst time includes indications for catheter ablation of select
asymptomatic patients. As detailed in Section 9, there are many
other additional clinical and imaging-based variables that can be
used to further deﬁne the efﬁcacy and risk of ablation in a given
patient. Some of the variables that can be used to deﬁne patients
in whom a lower success rate or a higher complication rate can be
expected include the presence of concomitant heart disease,
obesity, sleep apnea, left atrial (LA) size, patient age and frailty, as
well as the duration of time the patient has been in continuous AF.
Each of these variables needs to be considered when discussing
the risks and beneﬁts of AF ablation with a particular patient. In
the presence of substantial risk or anticipated difﬁculty of ablation,
it could be more appropriate to use additional antiarrhythmic drug
(AAD) options, even if the patient on face value might present with
a Class I or IIa indication for ablation. Third, it is important to
consider patient preference and values. Some patients are reluc-
tant to consider a major procedure or surgery and have a strong
preference for a pharmacological approach. In these patients, trials
of antiarrhythmic agents including amiodarone might be preferred
to catheter ablation. On the other hand, some patients prefer a
nonpharmacological approach. Fourth, it is important to recognize
that some patients early in the course of their AF journey might
have only infrequent episodes for many years and/or could have
AF that is responsive to well-tolerated AAD therapy. And ﬁnally, it
is important to bear in mind that a decision to perform catheter or
surgical AF ablation should only be made after a patient carefully
considers the risks, beneﬁts, and alternatives to the procedure.
Figure 6. Schematic of common lesion sets employed in AF ablation. A: The circumferential ablation lesions that are created in a circumferential fashion around the right and
the left PVs. The primary endpoint of this ablation strategy is the electrical isolation of the PV musculature. B: Some of the most common sites of linear ablation lesions.
These include a "roof line" connecting the lesions encircling the left and/or right PVs, a "mitral isthmus" line connecting the mitral valve and the lesion encircling the left PVs
at the end of the left inferior PV, and an anterior linear lesion connecting either the "roof line" or the left or right circumferential lesion to the mitral annulus anteriorly. A
linear lesion created at the cavotricuspid isthmus is also shown. This lesion is generally placed in patients who have experienced cavotricuspid isthmus-dependent atrial
ﬂutter clinically or have it induced during EP testing. C: Similar to 6B, but also shows additional linear ablation lesions between the superior and inferior PVs resulting in a
ﬁgure of eight lesion sets as well as a posterior inferior line allowing for electrical isolation of the posterior left atrial wall. An encircling lesion of the superior vena cava (SVC)
directed at electrical isolation of the SVC is also shown. SVC isolation is performed if focal ﬁring from the SVC can be demonstrated. A subset of operators empirically isolates
the SVC. D: Representative sites for ablation when targeting rotational activity or CFAEs are targeted.
Modiﬁed with permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
H. Calkins et al. / Journal of Arrhythmia 33 (2017) 369–409376Section 5: Strategies, Techniques, and Endpoints
The writing group recommendations for techniques to be used
for ablation of persistent and long-standing persistent AF (Table 3),
adjunctive ablation strategies, nonablative strategies to improve
outcomes of AF ablation, and endpoints for ablation of paroxysmal,
persistent, and long-standing persistent AF are covered in this
section. A schematic overview of common lesion sets created
during an AF ablation procedure is shown in Figure 6.Section 6: Technology and Tools
This section of the consensus statement provides an update on
many of the technologies and tools that are employed for AF
ablation procedures. It is important to recognize that this is not a
comprehensive listing and that new technologies, tools, and
approaches are being developed. It is also important to recognize
that radiofrequency (RF) energy is the dominant energy source
available for ablation of typical and atypical atrial ﬂutter (AFL).Although cryoablation is a commonly employed tool for AF abla-
tion, it is not well suited for ablation of typical or atypical AFL.
Other energy sources and tools are available in some parts of the
world and/or are in various stages of development and/or clinical
investigation. Shown in Figure 9 are schematic drawings of AF
ablation using point-by-point RF energy (Figure 9A) and AF abla-
tion using the cryoballoon (CB) system (Figure 9B).Section 7: Technical Aspects of Ablation to Maximize Safety and
Anticoagulation
Anticoagulation strategies pre-, during, and postcatheter abla-
tion of AF (Table 4); signs and symptoms of complications that can
occur within the ﬁrst several months following ablation (Table 5);
anesthesia or sedation during ablation; and approaches to mini-
mize risk of an atrial esophageal ﬁstula are discussed in this
section.
Table 2
Indications for catheter (A and B) and surgical (C, D, and E) ablation of atrial ﬁbrillation
Recommendation Class LOE References
Indications for catheter ablation of atrial ﬁbrillation
A. Indications for catheter ablation of atrial ﬁbrillation
Symptomatic AF refractory or intolerant to at least one
Class I or III antiarrhythmic medication
Paroxysmal: Catheter ablation is recommended. I A 7–18
Persistent: Catheter ablation is reasonable. IIa B-NR 8,16–26
Long-standing persistent: Catheter ablation may be considered. IIb C-LD 8,16–26
Symptomatic AF prior to initiation of antiarrhythmic
therapy with a Class I or III antiarrhythmic medication
Paroxysmal: Catheter ablation is reasonable. IIa B-R 27–35
Persistent: Catheter ablation is reasonable. IIa C-EO
Long-standing persistent: Catheter ablation may be considered. IIb C-EO
B. Indications for catheter atrial ﬁbrillation ablation in populations of patients not well represented in clinical trials
Congestive heart failure It is reasonable to use similar indications for AF ablation in selected patients with
heart failure as in patients without heart failure.
IIa B-R 36–52
Older patients (475 years of age) It is reasonable to use similar indications for AF ablation in selected older
patients with AF as in younger patients.
IIa B-NR 53–59
Hypertrophic cardiomyopathy It is reasonable to use similar indications for AF ablation in selected patients with
HCM as in patients without HCM.
IIa B-NR 60–62
Young patients (o45 years of age) It is reasonable to use similar indications for AF ablation in young patients with
AF (o45 years of age) as in older patients.
IIa B-NR 63,64
Tachy-brady syndrome It is reasonable to offer AF ablation as an alternative to pacemaker implantation
in patients with tachy-brady syndrome.
IIa B-NR 33–35
Athletes with AF It is reasonable to offer high-level athletes AF as ﬁrst-line therapy due to the
negative effects of medications on athletic performance.
IIa C-LD 27,28,65
Asymptomatic AFnn Paroxysmal: Catheter ablation may be considered in select patients.nn IIb C-EO 66,67
Persistent: Catheter ablation may be considered in select patients. IIb C-EO 68
Indications for surgical ablation of atrial ﬁbrillation
C. Indications for concomitant open (such as mitral valve) surgical ablation of atrial ﬁbrillation
Symptomatic AF refractory or intolerant to at least one
Class I or III antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR 69–82
Persistent: Surgical ablation is recommended. I B-NR 69–82
Long-standing persistent: Surgical ablation is recommended. I B-NR 69–82
Symptomatic AF prior to initiation of antiarrhythmic
therapy with a Class I or III antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR 69–82
Persistent: Surgical ablation is recommended. I B-NR 69–82
Long-standing persistent: Surgical ablation is recommended. I B-NR 69–82
D. Indications for concomitant closed (such as CABG and AVR) surgical ablation of atrial ﬁbrillation
Symptomatic AF refractory or intolerant to at least one
Class I or III antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR 83–88
Persistent: Surgical ablation is recommended. I B-NR 83–88
Long-standing persistent: Surgical ablation is recommended. I B-NR 83–88
Symptomatic AF prior to initiation of antiarrhythmic
therapy with a Class I or III antiarrhythmic medication
Paroxysmal: Surgical ablation is reasonable. IIa B-NR 83–88
Persistent: Surgical ablation is reasonable. IIa B-NR 83–88
Long-standing persistent: Surgical ablation is reasonable. IIa B-NR 83–88
E. Indications for stand-alone and hybrid surgical ablation of atrial ﬁbrillation
Symptomatic AF refractory or intolerant to at least one
Class I or III antiarrhythmic medication
Paroxysmal: Stand-alone surgical ablation can be considered for patients who
have failed one or more attempts at catheter ablation and also for those who are
intolerant or refractory to antiarrhythmic drug therapy and prefer a surgical
approach, after review of the relative safety and efﬁcacy of catheter ablation
versus a stand-alone surgical approach.
IIb B-NR 83–85,89–103
Persistent: Stand-alone surgical ablation is reasonable for patients who have
failed one or more attempts at catheter ablation and also for those patients who
prefer a surgical approach after review of the relative safety and efﬁcacy of
catheter ablation versus a stand-alone surgical approach.
IIa B-NR 83–85,89–103
Long-standing persistent: Stand-alone surgical ablation is reasonable for patients
who have failed one or more attempts at catheter ablation and also for those
patients who prefer a surgical approach after review of the relative safety and
efﬁcacy of catheter ablation versus a stand-alone surgical approach.
IIa B-NR 83–85,89–103
It might be reasonable to apply the indications for stand-alone surgical ablation
described above to patients being considered for hybrid surgical AF ablation.
IIb C-EO 103–108
AF ¼ atrial ﬁbrillation; LOE ¼ Level of Evidence; HCM ¼ hypertrophic cardiomyopathy.
nn A decision to perform AF ablation in an asymptomatic patient requires additional discussion with the patient because the potential beneﬁts of the procedure for the
patient without symptoms are uncertain.
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AF ablation is an invasive procedure that entails risks, most of
which are present during the acute procedural period. However,
complications can also occur in the weeks or months following
ablation. Recognizing common symptoms after AF ablation and
distinguishing those that require urgent evaluation and referral to
an electrophysiologist is an important part of follow-up after AF
ablation. The success of AF ablation is based in large part on
freedom from AF recurrence based on ECG monitoring. Arrhythmiamonitoring can be performed with the use of noncontinuous or
continuous ECG monitoring tools (Table 6). This section also dis-
cusses the important topics of AAD and non-AAD use prior to and
following AF ablation, the role of cardioversion, as well as the
indications for and timing of repeat AF ablation procedures.
Section 9: Outcomes and Efﬁcacy
This section provides a comprehensive review of the outcomes
of catheter ablation of AF. Table 7 summarizes the main ﬁndings of
Figure 7. Indications for catheter ablation of symptomatic atrial ﬁbrillation. Shown
in this ﬁgure are the indications for catheter ablation of symptomatic paroxysmal,
persistent, and long-standing persistent AF. The Class for each indication based on
whether ablation is performed after failure of antiarrhythmic drug therapy or as
ﬁrst-line therapy is shown. Please refer to Table 2B and the text for the indications
for catheter ablation of asymptomatic AF.
Figure 8. Indications for surgical ablation of atrial ﬁbrillation. Shown in this ﬁgure are
persistent AF. The Class for each indication based on whether ablation is performed a
indications for surgical AF ablation are divided into whether the AF ablation procedure
replacement), a closed surgical procedure (such as coronary artery bypass graft surgery),
atrial ﬁbrillation.
H. Calkins et al. / Journal of Arrhythmia 33 (2017) 369–409378the most important clinical trials in this ﬁeld. Outcomes of AF
ablation in subsets of patients not well represented in these trials
are reviewed. Outcomes for speciﬁc ablation systems and strate-
gies (CB ablation, rotational activity ablation, and laser balloon
ablation) are also reviewed.Section 10: Complications
Catheter ablation of AF is one of the most complex interven-
tional electrophysiological procedures. AF ablation by its nature
involves catheter manipulation and ablation in the delicate thin-
walled atria, which are in close proximity to other important
organs and structures that can be impacted through collateral
damage. It is therefore not surprising that AF ablation is associated
with a signiﬁcant risk of complications, some of which might
result in life-long disability and/or death. This section reviews the
complications associated with catheter ablation procedures per-
formed to treat AF. The types and incidence of complications are
presented, their mechanisms are explored, and the optimalthe indications for surgical ablation of paroxysmal, persistent, and long-standing
fter failure of antiarrhythmic drug therapy or as ﬁrst-line therapy is shown. The
is performed concomitantly with an open surgical procedure (such as mitral valve
or as a stand-alone surgical AF ablation procedure performed solely for treatment of
Table 3
Atrial ﬁbrillation ablation: strategies, techniques, and endpoints
Recommendation Class LOE References
PV isolation by catheter ablation Electrical isolation of the PVs is recommended during all AF ablation procedures. I A 7–16,19–26,109
Achievement of electrical isolation requires, at a minimum, assessment and demonstration of entrance block into the PV. I B-R 7–16,19–26,109
Monitoring for PV reconnection for 20 minutes following initial PV isolation is reasonable. IIa B-R 9,110–120
Administration of adenosine 20 minutes following initial PV isolation using RF energy with reablation if PV reconnection
might be considered.
IIb B-R 109,111–114,120–128
Use of a pace-capture (pacing along the ablation line) ablation strategy may be considered. IIb B-R 129–133
Demonstration of exit block may be considered. IIb B-NR 134–139
Ablation strategies to be considered for use in conjunction
with PV isolation
If a patient has a history of typical atrial ﬂutter or typical atrial ﬂutter is induced at the time of AF ablation, delivery of a
cavotricuspid isthmus linear lesion is recommended.
I B-R 140–143
If linear ablation lesions are applied, operators should use mapping and pacing maneuvers to assess for line completeness. I C-LD 19,141–149
If a reproducible focal trigger that initiates AF is identiﬁed outside the PV ostia at the time of an AF ablation procedure,
ablation of the focal trigger should be considered.
IIa C-LD 150–161
When performing AF ablation with a force-sensing RF ablation catheter, a minimal targeted contact force of 5 to 10 grams is
reasonable.
IIa C-LD 13,14,128,162–178
Posterior wall isolation might be considered for initial or repeat ablation of persistent or long-standing persistent AF. IIb C-LD 21,179–185
Administration of high-dose isoproterenol to screen for and then ablate non-PV triggers may be considered during initial or
repeat AF ablation procedures in patients with paroxysmal, persistent, or long-standing persistent AF.
IIb C-LD 150–161
DF-based ablation strategy is of unknown usefulness for AF ablation. IIb C-LD 186–193
The usefulness of creating linear ablation lesions in the right or left atrium as an initial or repeat ablation strategy for
persistent or long-standing persistent AF is not well established.
IIb B-NR 19,20,142,145–149,194–201
The usefulness of linear ablation lesions in the absence of macroreentrant atrial ﬂutter is not well established. IIb C-LD 19,20,142,145–149,194–201
The usefulness of mapping and ablation of areas of abnormal myocardial tissue identiﬁed with voltage mapping or MRI as
an initial or repeat ablation strategy for persistent or long-standing persistent AF is not well established.
IIb B-R 179,202–211
The usefulness of ablation of complex fractionated atrial electrograms as an initial or repeat ablation strategy for persistent
and long-standing persistent AF is not well established.
IIb B-R 19,20,195–197,212–220
The usefulness of ablation of rotational activity as an initial or repeat ablation strategy for persistent and long-standing
persistent AF is not well established.
IIb B-NR 221–241
The usefulness of ablation of autonomic ganglia as an initial or repeat ablation strategy for paroxysmal, persistent, and long-
standing persistent AF is not well established.
IIb B-NR 19,89,242–259
Nonablation strategies to improve outcomes Weight loss can be useful for patients with AF, including those who are being evaluated to undergo an AF ablation pro-
cedure, as part of a comprehensive risk factor management strategy.
IIa B-R 260–288
It is reasonable to consider a patient's BMI when discussing the risks, beneﬁts, and outcomes of AF ablation with a patient
being evaluated for an AF ablation procedure.
IIa B-R 260–288
It is reasonable to screen for signs and symptoms of sleep apnea when evaluating a patient for an AF ablation procedure and
to recommend a sleep evaluation if sleep apnea is suspected.
IIa B-R 270,276–278,289–307
Treatment of sleep apnea can be useful for patients with AF, including those who are being evaluated to undergo an AF
ablation procedure.
IIa B-R 270,276–278,289–307
The usefulness of discontinuation of antiarrhythmic drug therapy prior to AF ablation in an effort to improve long-term
outcomes is unclear.
IIb C-LD 308–312
The usefulness of initiation or continuation of antiarrhythmic drug therapy during the postablation healing phase in an
effort to improve long-term outcomes is unclear.
IIb C-LD 308–312
Strategies to reduce the risks of AF ablation Careful identiﬁcation of the PV ostia is mandatory to avoid ablation within the PVs. I B-NR 313–335
It is recommended that RF power be reduced when creating lesions along the posterior wall near the esophagus. I C-LD 68,336–365
It is reasonable to use an esophageal temperature probe during AF ablation procedures to monitor esophageal temperature
and help guide energy delivery.
IIa C-EO 68,336,345,365
AF ¼ atrial ﬁbrillation; LOE ¼ Level of Evidence; PV ¼ pulmonary vein; RF ¼ radiofrequency; MRI ¼ magnetic resonance imaging; BMI ¼ body mass index.
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Figure 9. Schematic drawing showing catheter ablation of atrial ﬁbrillation using either RF energy or cryoballoon AF ablation. A: Shows a typical wide area lesion set created
using RF energy. Ablation lesions are delivered in a ﬁgure of eight pattern around the left and right PV veins. Also shown is a linear cavotricuspid isthmus lesion created for
ablation of typical atrial ﬂutter in a patient with a prior history of typical atrial ﬂutter or inducible isthmus-dependent typical atrial ﬂutter at the time of ablation. A
multielectrode circular mapping catheter is positioned in the left inferior PV. B: Shows an ablation procedure using the cryoballoon system. Ablation lesions have been
created surrounding the right PVs, and the cryoballoon ablation catheter is positioned in the left superior PV. A through the lumen multielectrode circular mapping catheter
is positioned in the left superior PV.
Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
Table 4
Anticoagulation strategies: pre-, during, and postcatheter ablation of AF
Recommendation Class LOE References
Preablation For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with warfarin or dabi-
gatran, performance of the ablation procedure without interruption of warfarin or dabigatran is recommended.
I A 366–373
For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with rivaroxaban, per-
formance of the ablation procedure without interruption of rivaroxaban is recommended.
I B-R 374
For patients undergoing AF catheter ablation who have been therapeutically anticoagulated with a NOAC other than
dabigatran or rivaroxaban, performance of the ablation procedure without withholding a NOAC dose is reasonable.
IIa B-NR 375
Anticoagulation guidelines that pertain to cardioversion of AF should be adhered to in patients who present for an AF
catheter ablation procedure.
I B-NR 5,6
For patients anticoagulated with a NOAC prior to AF catheter ablation, it is reasonable to hold one to two doses of the
NOAC prior to AF ablation with reinitiation postablation.
IIa B-NR 372,376–380
Performance of a TEE in patients who are in AF on presentation for AF catheter ablation and who have been receiving
anticoagulation therapeutically for 3 weeks or longer is reasonable.
IIa C-EO 5,6
Performance of a TEE in patients who present for ablation in sinus rhythm and who have not been anticoagulated
prior to catheter ablation is reasonable.
IIa C-EO 5,6
Use of intracardiac echocardiography to screen for atrial thrombi in patients who cannot undergo TEE may be
considered.
IIb C-EO 381–386
During ablation Heparin should be administered prior to or immediately following transseptal puncture during AF catheter ablation
procedures and adjusted to achieve and maintain an ACT of at least 300 seconds.
I B-NR 369,380–382,387–393
Administration of protamine following AF catheter ablation to reverse heparin is reasonable. IIa B-NR 394
Postablation In patients who are not therapeutically anticoagulated prior to catheter ablation of AF and in whom warfarin will be
used for anticoagulation postablation, low molecular weight heparin or intravenous heparin should be used as a
bridge for initiation of systemic anticoagulation with warfarin following AF ablation.n
I C-EO
Systemic anticoagulation with warfarinn or a NOAC is recommended for at least 2 months postcatheter ablation of AF. I C-EO 1,2
Adherence to AF anticoagulation guidelines is recommended for patients who have undergone an AF ablation pro-
cedure, regardless of the apparent success or failure of the procedure.
I C-EO 5,6
Decisions regarding continuation of systemic anticoagulation more than 2 months post ablation should be based on
the patient's stroke risk proﬁle and not on the perceived success or failure of the ablation procedure.
I C-EO 5,6
In patients who have not been anticoagulated prior to catheter ablation of AF or in whom anticoagulation with a NOAC
or warfarin has been interrupted prior to ablation, administration of a NOAC 3 to 5 hours after achievement of
hemostasis is reasonable postablation.
IIa C-EO 372,376–380
Patients in whom discontinuation of anticoagulation is being considered based on patient values and preferences
should consider undergoing continuous or frequent ECG monitoring to screen for AF recurrence.
IIb C-EO
AF ¼ atrial ﬁbrillation; LOE ¼ Level of Evidence; NOAC ¼ novel oral anticoagulant; TEE ¼ transesophageal electrocardiogram; ACT ¼ activated clotting time.
n Time in therapeutic range (TTR) should be 4 65% – 70% on warfarin.
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Table 5
Signs and symptoms following AF ablation
Differential Suggested evaluation
Signs and symptoms of complications within a month postablation
Back pain Musculoskeletal, retroperitoneal hematoma Physical exam, CT imaging
Chest pain Pericarditis, pericardial effusion, coronary stenosis (ablation related), pul-
monary vein stenosis, musculoskeletal (after cardioversion), worsening
reﬂux
Physical exam, chest X-ray, ECG, echocardiogram,
stress test, cardiac catheterization, chest CT
Cough Infectious process, bronchial irritation (mechanical, cryoballoon), pulmonary
vein stenosis
Physical exam, chest X-ray, chest CT
Dysphagia Esophageal irritation (related to transesophageal echocardiography),
atrioesophageal ﬁstula
Physical exam, chest CT or MRI
Early satiety, nausea Gastric denervation Physical exam, gastric emptying study
Fever Infectious process, pericarditis, atrioesophageal ﬁstula Physical exam, chest X-ray, chest CT, urinalysis,
laboratory blood work
Fever, dysphagia, neurological
symptoms
Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest CT or MRI;
avoid endoscopy with air insufﬂation
Groin pain at site of access Pseudoaneurysm, AV ﬁstula, hematoma Ultrasound of the groin, laboratory blood work; con-
sider CT scan if ultrasound negative
Headache Migraine (related to anesthesia or transseptal access, hemorrhagic stroke),
effect of general anesthetic
Physical exam, brain imaging (MRI)
Hypotension Pericardial effusion/tamponade, bleeding, sepsis, persistent vagal reaction Echocardiography, laboratory blood work
Hemoptysis PV stenosis or occlusion, pneumonia Chest X-ray, chest CT or MR scan, VQ scan
Neurological symptoms Cerebral embolic event, atrial esophageal ﬁstula Physical exam, brain imaging, chest CT or MRI
Shortness of breath Volume overload, pneumonia, pulmonary vein stenosis, phrenic nerve injury Physical exam, chest X-ray, chest CT, laboratory blood
work
Signs and symptoms of complications more than a month postablation
Fever, dysphagia, neurological
symptoms
Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest CT or MRI;
avoid endoscopy with air insufﬂation
Persistent cough, atypical
chest pain
Infectious process, pulmonary vein stenosis Physical exam, laboratory blood work, chest X-ray,
chest CT or MRI
Neurological symptoms Cerebral embolic event, atrial esophageal ﬁstula Physical exam, brain imaging, chest CT or MRI
Hemoptysis PV stenosis or occlusion, pneumonia CT scan, VQ scan
AF ¼ atrial ﬁbrillation; ECG ¼ electrocardiogram; CT ¼ computed tomography; MRI ¼ magnetic resonance imaging; VQ ¼ ventilation-perfusion.
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9).Section 11: Training Requirements
This section of the document outlines the training require-
ments for those who wish to perform catheter ablation of AF.Section 12: Surgical and Hybrid AF Ablation
Please refer to Table 2 and Figure 8 presented earlier in this
Executive Summary.Section 13: Clinical Trial Design
Although there have been many advances made in the ﬁeld of
catheter and surgical ablation of AF, there is still much to be
learned about the mechanisms of initiation and maintenance of AF
and how to apply this knowledge to the still-evolving techniques
of AF ablation. Although single-center, observational reports have
dominated the early days of this ﬁeld, we are quickly moving into
an era in which hypotheses are put through the rigor of testing in
well-designed, randomized, multicenter clinical trials. It is as a
result of these trials that conventional thinking about the best
techniques, success rates, complication rates, and long-term out-
comes beyond AF recurrence–such as thromboembolism and
mortality–is being put to the test. The ablation literature has alsoseen a proliferation of meta-analyses and other aggregate ana-
lyses, which reinforce the need for consistency in the approach to
reporting the results of clinical trials. This section reviews the
minimum requirements for reporting on AF ablation trials. It also
acknowledges the potential limitations of using speciﬁc primary
outcomes and emphasizes the need for broad and consistent
reporting of secondary outcomes to assist the end-user in deter-
mining not only the scientiﬁc, but also the clinical relevance of the
results (Tables 10–13).Unanswered Questions in AF Ablation
There is still much to be learned about the mechanisms of AF,
techniques of AF ablation, and long-term outcomes. The following
are unanswered questions for future investigation:
1. AF ablation and modiﬁcation of stroke risk and need for
ongoing oral anticoagulation (OAC): The CHA2DS2-VASc score
was developed for patients with clinical AF. If a patient has
received a successful ablation such that he/she no longer has
clinical AF (subclinical, or no AF), then what is the need for
ongoing OAC? Are there any patients in whom successful
ablation could lead to discontinuation of OAC?
2. Substrate modiﬁcation in catheter-based management of AF–
particularly for persistent AF: What is the proper lesion set
required beyond pulmonary vein isolation? Do lines and
complex fractionated atrial electrogram (CFAE) have any
remaining role? Are these approaches ill-advised or simply
discouraged?
Table 6
Types of ambulatory cardiac monitoring devices
Type of recorder Typical monitoring duration Continuous recording Event recording Auto trigger Unique features
Holter monitor 24–48 hours, approximately 7–
30 days
Yes Yes N/A Short term, provides quantitative data on arrhythmia burden
Patch monitor 1–3 weeks Yes Yes N/A Intermediate term, can provide continuous data for up to several weeks; improved patient com-
pliance without lead wires
External loop recorder 1 month Yes Yes Variable Good correlation between symptoms and even brief arrhythmias
External nonloop recorder Months No Yes No May be used long term and intermittently; will not capture very brief episodes
Smartphone monitor Indeﬁnite No Yes No Provides inexpensive long-term intermittent monitoring; dependent on patient compliance;
requires a smartphone
Mobile cardiac telemetry 30 days Yes Yes Yes Real time central monitoring and alarms; relatively expensive
Implantable loop recorder Up to 3 years Yes Yes Yes Improved patient compliance for long-term use; not able to detect 30-second episodes of AF due to
detection algorithm; presence of AF needs to be conﬁrmed by EGM review because speciﬁcity of
detection algorithm is imperfect; expensive
Pacemakers or ICDs with atrial
leads
Indeﬁnite Yes Yes Yes Excellent AF documentation of burden and trends; presence of AF needs to be conﬁrmed by
electrogram tracing review because speciﬁcity of detection algorithms is imperfect; expensive
Wearable multisensor ECG
monitors
Indeﬁnite Yes Yes Yes ECG 3 leads, temp, heart rate, HRV, activity tracking, respiratory rate, galvanic skin response
AF ¼ atrial ﬁbrillation; ICD ¼ implantable cardioverter deﬁbrillator; ECG ¼ electrocardiogram; HRV ¼ heart rate variability.
Table 7
Selected clinical trials of catheter ablation of atrial ﬁbrillation and/or for FDA approval
Trial Year Type N AF type Ablation
strategy
Initial
time
frame
Effectiveness
endpoint
Ablation success Drug/
Control
success
P value for
success
Ablation
complications
Drug/Control
complications
Comments
Clinical Trials Per-
formed for FDA
Approval
JAMA 2010; 303:
333-340
(ThermoCoolAF)14
2010 Randomized to RF
ablation or AAD,
multicenter
167 Paroxysmal PVI,
optional
CFAEs and
lines
12
months
Freedom from
symptomatic par-
oxysmal atrial
ﬁbrillation, acute
procedural failure,
or changes in spe-
ciﬁed drug regimen
66% 16% o0.001 4.9% 8.8% FDA
approval
received
JACC 2013; 61: 1713-
1723 (STOP AF)9
2013 Randomized to cryo-
balloon ablation or
AAD, multicenter
245 Paroxysmal PVI 12
months
Freedom from any
detectable AF, use of
nonstudy AAD, or
nonprotocol inter-
vention for AF
70% 7% o0.001 3.1% NA FDA
approval
received
Heart Rhythm 2014;
11: 202-209 (TTOP)22
2014 Randomized to phased
RF ablation or AAD/
cardioversion,
multicenter
210 Persistent PVI þ CFAEs 6
months
Acute procedural
success, Z90%
reduction in AF
burden, off AAD
56% 26% o0.001 12.3% NA Not FDA
approved
JACC 2014; 64: 647-
656 (SMART-AF)13
2014 Nonrandomzied mul-
ticenter study of
172 Paroxysmal PVI,
optional
12
months
Freedom from
symptomatic AF,
72.5% N/A o0.0001 7.5% NA
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contact force-sensing
RF catheter, compar-
ing to performance
goals
CFAEs and
lines
ﬂutter, tachycardia,
acute procedural
failure, or changes
in AAD
FDA
approval
received
Circulation 2015;
132: 907-915
(TOCCASTAR)12
2015 Randomized to con-
tact force sensing RF
catheter or approved
RF catheter,
multicenter
300 Paroxysaml PVI,
optional
triggers,
CAFEs and
lines in both
arms
12
months
Acute procedural
success þ Freedom
from Symptomatic
AF/Flutter/Tachy-
cardia off AAD
67.8% 69.4% 0.0073 for
noninferiority
7.2% 9.1% FDA
approval
received
JACC 2015; 66: 1350-
1360 (HeartLight)11
2015 Randomized to laser-
balloon or approved
RF catheter,
multicenter
353 Paroxysmal PVI 7 CTI
ablation vs
PVI,
optional
CFAEs, and
Lines
12
months
Freedom from
Symptomatic AF/
Flutter/Tachycardia,
acute procedural
failure, AAD, or
non-prototocol
intervention
61.1% 61.7% 0.003 for
noninferiority
5.3% 6.4% FDA
approval
received
First-Line Therapy
Trials
JAMA 2005; 293:
2634-2640 (RAAFT)29
2005 Randomized to drug,
multicenter
70 Paroxysmal
(N¼67), per-
sistent (N¼ 3)
PVI 12
months
Freedom from
detectable AF
84% 37% o0.01 9% 11%
NEJM 2012;
367:1587-1595
(MANTRA-PAF)30
2012 Randomized to drug,
multicenter
294 Paroxysmal AF PVI, roof
line,
optional
mitral and
tricuspid
line
24
months
Cumulative AF
burden
13% AF burden 19% AF
burden
NS 17% 15%
JAMA 2014; 311:
692-700 (RAAFT-2)31
2014 Randomized to drug
multicenter
127 Paroxysmal AF PVI plus
optional
non-PVI
targets
24
months
Freedom from
detectable AF, ﬂut-
ter, tachycardia
45% 28% 0.02 9% 4.9%
Other Paroxysmal AF
Ablation Trials
JACC 2006; 48: 2340-
2347 (APAF)16
2006 Randomized to drug
single center
198 Paroxysmal AF PVI, mitral
line and tri-
cuspid line
12
months
Freedom from
detectable AF, ﬂut-
ter, tachycardia
86% 22% o0.001 1% 23%
Circulation 2008;
118: 2498-2505 (A4)7
2008 Randomized to drug 112 Paroxysmal PVI
(optional LA
lines, CTI,
focal)
12
months
Freedom from AF 89% 23% o0.0001 5.7% 1.7%
NEJM 2016; 374:
2235-2245 (FIRE
AND ICE)10
2016 Randomized RF vs
Cryo, multicenter
762 Paroxysmal AF PVI 12
months
Freedom from
detectable AF, ﬂut-
ter, tachycardia
64.1% (RF) 65.4%
(cryo)
NS 12.8% 10.2%
JACC 2016; 68: 2747-
275715
2016 Randomized to hot
balloon or drug,
multicenter
100 Paroxysmal AF PVI 12
months
Freedom from AF 59% 5% o0.001 10.4% 4.7%
Other Persistent AF
Ablation Trials
NEJM 2006; 354:
934-94125
2006 Randomized to RF
ablation or to CV and
short term amio
146 Persistent PVI, roof,
mitral line
12
months
No AF or ﬂutter
month 12
74% 58% 0.05 1.3% 1.4%
EHJ 2014; 35: 501-
507 (SARA)26
2014 Randomized to drug
(2:1 ablation to drug),
multicenter
146 Persistent PVI
(optional LA
lines, CFAEs)
12
months
Freedom from AF/
ﬂutter lasting
424h
70% 44% 0.002 6.1% 4.20%
NEJM 2015; 372:
1812-182219
2015 Randomized ablation
strategies, multicenter
589 Persistent PVI alone
versus PVI &
CFAEs or PVI
& lines
18
months
Freedom from aﬁb
with or without
drugs
59% (PVI alone) 49% & 46% NS 6% 4.3% & 7.6%
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Table 7 (continued )
Trial Year Type N AF type Ablation
strategy
Initial
time
frame
Effectiveness
endpoint
Ablation success Drug/
Control
success
P value for
success
Ablation
complications
Drug/Control
complications
Comments
Other Mixed Parox-
ysmal and Persistent
AF Ablation Trials
J Med Assoc Thai
2003; 86 (Suppl 1):
S8-S1624
2003 Randomized to RF
ablation or
amiodarone
30 Paroxysmal
(70%), Persis-
tent (30%)
PVI, mitral
line, CTI,
SVC to IVC
12
months
Freedom from AF 79% 40% 0.018 6.70% 47%
EHJ 2006; 27: 216-
22117
2006 Randomized to RF
ablation or drug,
multicenter
137 Paroxysmal
(67%), Persis-
tent (33%)
PVI, mitral
line, CTI
12
months
Freedom from AF,
ﬂutter, tachycardia
66% 9% o0.001 4.40% 2.90%
JCVEP 2009, 20: 22-
2818
2009 Randomized to RF
ablation or drug,
multicenter
70 Paroxysmal
(41%), Persis-
tent (59%) &
type 2 DM
PVI, CTI,
optional
mitral line
and roof
line
12
months
Freedom from AF
and atypical atrial
ﬂutter
80% 43% 0.001 2.90% 17%
Randomized Trials of
AF Ablation in
Patients with Heart
Failure
NEJM 2008; 359:
1778-1785 (PABA-
HF)38
2008 Randomized to RF
ablation of AVJ abl and
BiV pacing
81 Persistent
(50%), Parox-
ysmal (50%),
EF 27% abl, 29%
AVJ
PVI,
optional lin-
ear abl and
CFAEs
6
months
Composite EF, 6 min
walk, MLWHF
score; freedom from
AF (secondary, mult
proc, þ/- AA drugs)
88% AF free, EF
35% abl, 28% AVJ
(P o .001), 4
QOL and 6 min
walk increase
with abl
o0.001 14.60% 17.50%
Heart 2011; 97: 740-
74739
2011 Randomized to RF
ablation or pharmaco-
logical rate control
41 Persistent , EF
20% abl, 16%
rate control
PVI, roof
line, CFAEs
6
months
Change in LVEF,
sinus rhythm at
6 months
(secondary)
50% in NSR, LVEF
increase 4.5%
0% in NSR,
LVEF
increase
2.8%
0.6 (for EF
increase)
15% Not reported
JACC 2013; 61: 1894-
190346
2013 Randomized to RF
ablation or pharmaco-
logical rate control
52 Persistent AF
(100%), EF 22%
abl, 25% rate
control
PVI,
optional lin-
ear abl and
CFAEs
12
months
Change in peak O2
consumption (also
reported single
procedure off drug
ablation success)
Peak O2 con-
sumption increase
greater with abl,
72% abl success
0.018 15% Not reported
Circ A and E 2014;
7:31-3840
2014 Randomized to RF
ablation or pharmaco-
logical rate control
50 Persistent AF
(100%), EF 32%
abl, 34% rate
control
PVI,
optional lin-
ear abl and
CFAEs
6
months
Change in LVEF at
6 months, multiple
procedure freedom
from AF also
reported
LVEF 40% with abl,
31% rate control,
81% AF free with
abl
0.015 7.70%
AF ¼ atrial ﬁbrillation; RF ¼ radiofrequency; AVJ ¼ atrioventricular junction; abl ¼ ablation; BiV ¼ biventricular; EF ¼ ejection fraction; PVI ¼ pulmonary vein isolation; CFAEs ¼ complex fractionated atrial electrograms;
MLWHF ¼ Minnesota Living with Heart Failure; LVEF ¼ left ventricular ejection fraction; QOL ¼ quality of life; NSR ¼ normal sinus rhythm.
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Table 8
Deﬁnitions of complications associated with AF ablation
Asymptomatic cerebral embolism Asymptomatic cerebral embolism is deﬁned as an occlusion of a blood vessel in the brain due to an embolus that
does not result in any acute clinical symptoms. Silent cerebral embolism is generally detected using a diffusion
weighted MRI.
Atrioesophageal ﬁstula An atrioesophageal ﬁstula is deﬁned as a connection between the atrium and the lumen of the esophagus.
Evidence supporting this diagnosis includes documentation of esophageal erosion combined with evidence of a
ﬁstulous connection to the atrium, such as air emboli, an embolic event, or direct observation at the time of
surgical repair. A CT scan or MRI scan is the most common method of documentation of an atrioesophageal
ﬁstula.
Bleeding Bleeding is deﬁned as a major complication of AF ablation if it requires and/or is treated with transfusion or
results in a 20% or greater fall in hematocrit.
Bleeding following cardiac surgery Excessive bleeding following a surgical AF ablation procedure is deﬁned as bleeding requiring reoperation or Z2
units of PRBC transfusion within any 24 hours of the ﬁrst 7 days following the index procedure.
Cardiac perforation We recommend that cardiac perforation be deﬁned together with cardiac tamponade. See "Cardiac tamponade/
perforation."
Cardiac tamponade We recommend that cardiac tamponade be deﬁned together with cardiac perforation. See "Cardiac tamponade/
perforation."
Cardiac tamponade/perforation Cardiac tamponade/perforation is deﬁned as the development of a signiﬁcant pericardial effusion during or
within 30 days of undergoing an AF ablation procedure. A signiﬁcant pericardial effusion is one that results in
hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm or more peri-
cardial effusion as documented by echocardiography. Cardiac tamponade/perforation should also be classiﬁed as
"early" or "late" depending on whether it is diagnosed during or following initial discharge from the hospital.
Deep sternal wound infection/mediastinitis following
cardiac surgery
Deep sternal wound infection/mediastinitis following cardiac surgery requires one of the following: (1) an
organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed during
surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (438°C), in combination
with either purulent discharge from the mediastinum or an organism isolated from blood culture or culture of
mediastinal drainage.
Esophageal injury Esophageal injury is deﬁned as an erosion, ulceration, or perforation of the esophagus. The method of screening
for esophageal injury should be speciﬁed. Esophageal injury can be a mild complication (erosion or ulceration) or
a major complication (perforation).
Gastric motility/pyloric spasm disorders Gastric motility/pyloric spasm disorder should be considered a major complication of AF ablation when it
prolongs or requires hospitalization, requires intervention, or results in late disability, such as weight loss, early
satiety, diarrhea, or GI disturbance.
Major complication A major complication is a complication that results in permanent injury or death, requires intervention for
treatment, or prolongs or requires hospitalization for more than 48 hours. Because early recurrences of AF/AFL/
AT are to be expected following AF ablation, recurrent AF/AFL/AT within 3 months that requires or prolongs a
patient's hospitalization should not be considered to be a major complication of AF ablation.
Mediastinitis Mediastinitis is deﬁned as inﬂammation of the mediastinum. Diagnosis requires one of the following: (1) an
organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed during
surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (438°C), in combination
with either purulent discharge from the mediastinum or an organism isolated from blood culture or culture of
mediastinal drainage.
Myocardial infarction in the context of AF ablation The universal deﬁnition of myocardial infarction395 cannot be applied in the context of catheter or surgical AF
ablation procedures because it relies heavily on cardiac biomarkers (troponin and CPK), which are anticipated to
increase in all patients who undergo AF ablation as a result of the ablation of myocardial tissue. Similarly, chest
pain and other cardiac symptoms are difﬁcult to interpret in the context of AF ablation both because of the
required sedation and anesthesia and also because most patients experience chest pain following the procedure
as a result of the associated pericarditis that occurs following catheter ablation. We therefore propose that a
myocardial infarction, in the context of catheter or surgical ablation, be deﬁned as the presence of any one of the
following criteria: (1) detection of ECG changes indicative of new ischemia (new ST-T wave changes or new
LBBB) that persist for more than 1 hour; (2) development of new pathological Q waves on an ECG; (3) imaging
evidence of new loss of viable myocardium or new regional wall motion abnormality.
Pericarditis Pericarditis should be considered a major complication following ablation if it results in an effusion that leads to
hemodynamic compromise or requires pericardiocentesis, prolongs hospitalization by more than 48 hours,
requires hospitalization, or persists for more than 30 days following the ablation procedure.
Phrenic nerve paralysis Phrenic nerve paralysis is deﬁned as absent phrenic nerve function as assessed by a sniff test. A phrenic nerve
paralysis is considered to be permanent when it is documented to be present 12 months or longer following
ablation.
Pulmonary vein stenosis Pulmonary vein stenosis is deﬁned as a reduction of the diameter of a PV or PV branch. PV stenosis can be
categorized as mild o50%, moderate 50%–70%, and severe Z70% reduction in the diameter of the PV or PV
branch. A severe PV stenosis should be considered a major complication of AF ablation.
Serious adverse device effect A serious adverse device effect is deﬁned as a serious adverse event that is attributed to use of a particular
device.
Stiff left atrial syndrome Stiff left atrial syndrome is a clinical syndrome deﬁned by the presence of signs of right heart failure in the
presence of preserved LV function, pulmonary hypertension (mean PA pressure 425 mm Hg or during exercise
430 mm Hg), and large V waves Z10 mm Hg or higher) on PCWP or left atrial pressure tracings in the absence
of signiﬁcant mitral valve disease or PV stenosis.
Stroke or TIA postablation Stroke diagnostic criteria
 Rapid onset of a focal or global neurological deﬁcit with at least one of the following: change in level of
consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia
or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke
 Duration of a focal or global neurological deﬁcit Z24 hours; OR o24 hours if therapeutic intervention
(s) were performed (e.g., thrombolytic therapy or intracranial angioplasty); OR available neuroimaging
documents a new hemorrhage or infarct; OR the neurological deﬁcit results in death.
 No other readily identiﬁable nonstroke cause for the clinical presentation (e.g., brain tumor, trauma, infec-
tion, hypoglycemia, peripheral lesion, pharmacological inﬂuences).n
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 Conﬁrmation of the diagnosis by at least one of the following: neurology or neurosurgical specialist; neu-
roimaging procedure (MRI or CT scan or cerebral angiography); lumbar puncture (i.e., spinal ﬂuid analysis
diagnostic of intracranial hemorrhage)
Stroke deﬁnitions
 Transient ischemic attack: new focal neurological deﬁcit with rapid symptom resolution (usually 1 to
2 hours), always within 24 hours; neuroimaging without tissue injury
 Stroke: (diagnosis as above, preferably with positive neuroimaging study);
Minor–Modiﬁed Rankin score o2 at 30 and 90 days†
Major–Modiﬁed Rankin score Z2 at 30 and 90 days
Unanticipated adverse device effect Unanticipated adverse device effect is deﬁned as complication of an ablation procedure that has not been
previously known to be associated with catheter or surgical ablation procedures.
Vagal nerve injury Vagal nerve injury is deﬁned as injury to the vagal nerve that results in esophageal dysmotility or gastroparesis.
Vagal nerve injury is considered to be a major complication if it prolongs hospitalization, requires hospitaliza-
tion, or results in ongoing symptoms for more than 30 days following an ablation procedure.
Vascular access complication Vascular access complications include development of a hematoma, an AV ﬁstula, or a pseudoaneurysm. A major
vascular complication is deﬁned as one that requires intervention, such as surgical repair or transfusion, pro-
longs the hospital stay, or requires hospital admission.
AF ¼ atrial ﬁbrillation; CT ¼ computed tomography; MRI ¼ magnetic resonance imaging; PRBC ¼ packed red blood cell; AFL ¼ atrial ﬂutter; AT ¼ atrial tachycardia; CPK ¼
creatine phosphokinase; ECG ¼ electrocardiogram; LBBB ¼ left bundle branch block.
n Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal evidence based on neuroimaging studies.
† Modiﬁed Rankin score assessments should be made by qualiﬁed individuals according to a certiﬁcation process. If there is discordance between the 30- and 90-day
modiﬁed Rankin scores, a ﬁnal determination of major versus minor stroke will be adjudicated by the neurology members of the clinical events committee.
H. Calkins et al. / Journal of Arrhythmia 33 (2017) 369–409386What is the role of targeting localized rotational activations?
How do we ablate a localized rotational activation? How can
scar be characterized and targeted for ablation? Do we need to
replicate the MAZE procedure? Does the right atrium need to be
targeted as well as the left atrium?
3. Autonomic inﬂuence in AF: Is clinical AF really an autonomic
mediated arrhythmia? Is elimination of ganglionated plexi
required? Is there a role for autonomic modulation, for example,
spinal cord or vagal stimulation?
4. Contribution and modulation of risk factors on outcomes of AF
ablation: Obesity reduction has been shown to reduce AF bur-
den and recurrence in patients undergoing ablation. What is the
role of bariatric surgery? Does the modulation of other risk
factors inﬂuence outcome such as hypertension, sleep apnea,
and diabetes?
5. Outcomes in ablation of high-risk populations: Do high-risk
populations beneﬁt from AF ablation? Congestive heart failure
has been assessed in smaller trials, but larger trials are required.
Outcome data are needed in patients with very enlarged LAs,
hypertrophic cardiomyopathy, patients with renal failure on
dialysis, and the very elderly.
6. Surgical vs catheter-based vs hybrid ablation: There should be
more comparative work between percutaneous and minimally
invasive surgical approaches. Both report similar outcomes, but
there is a dearth of comparative data. Is there any patient
beneﬁt to hybrid procedures?
7. How do we characterize patients who are optimal candidates
for ablation? Preablation late gadolinium-enhanced (LGE)-magnetic resonance imaging (MRI) might identify patients with
heavy burdens of scar who are unlikely to respond to ablation.
These techniques must become reproducible and reliable and
must be assessed in multicenter trials. Other markers need to be
investigated, including genetic markers, biochemical markers,
and clinical markers based on aggregated risk scores.
8. The incremental role of new technologies: As newer and often
more expensive technologies are produced for AF ablation, their
deﬁnitive incremental value must be determined in order to
justify change in practice or case cost. These technologies
include global (basket) mapping techniques, newer ablation
indices for assessing lesion durability, advanced imaging for
viewing lesions in the myocardium, etc. New energy sources,
including laser, low-intensity ultrasound, photonic particle
therapy, external beam ablation, and MRI-guided ablation, must
be assessed in comparative fashion.
9. Outcomes of AF ablation: We need to better understand the
clinical relevance of ablation outcomes. What is the signiﬁcance
of time to recurrence of 30 seconds of arrhythmia? How do we
best quantify AF burden? How do these outcomes relate to
quality of life and stroke risk?
0. What is the role of surgical LA reduction? Does left atrial
appendage (LAA) occlusion or obliteration improve outcome of
persistent AF ablation with an accompanying reduction in
stroke? Does ablation work through atrial size reduction? What
is the incidence of "stiff atrial" syndrome and does this mitigate
the clinical impact of ablation?
Table 9
Incidence, prevention, diagnosis, and treatment of selected complications of AF ablation
Complication Incidence Selected prevention techniques Diagnostic testing Selected treatment options References
Air embolism o1% Sheath management Nothing or cardiac catheterization Supportive care with ﬂuid, oxygen,
head down tilt, hyperbaric oxygen
388,396–401
Asymptomatic cerebral
emboli (ACE)
2% to 15% Anticoagulation, catheter and sheath management, TEE Brain MRI None 402–419
Atrial esophageal ﬁstula 0.02% to
0.11%
Reduce power, force, and RF time on posterior wall, moni-
tor esophageal temp, use proton pump inhibitors; avoid
energy delivery over esophagus
CT scan of chest, MRI; avoid endo-
scopy with air insufﬂation
Surgical repair 337–365,420–456
Cardiac tamponade 0.2% to 5% Cather manipulation, transseptal technique, reduce power,
force, and RF time
Echocardiography Pericardiocentesis or surgical drainage 338,343,347,457–467
Coronary artery stenosis/
occlusion
o0.1% Avoid high-power energy delivery near coronary arteries Cardiac catheterization PTCA 468–476
Death o0.1% to
0.4%
Meticulous performance of procedure, attentive post-
procedure care
NA NA 338,343,347,458,477
Gastric hypomotility 0% to 17% Reduce power, force, and RF time on posterior wall Endoscopy, barium swallow, gastric
emptying study
Metoclopramide, possibly intravenous
erythromycin
478–490
Mitral valve entrapment o0.1% Avoid circular catheter placement near or across mitral
valve; clockwise torque on catheter
Echocardiography Gentle catheter manipulation, surgical
extraction
491–498
Pericarditis 0% to 50% None proven Clinical history, ECG, sedimentation
rate, echocardiogram
NSAID, colchicine, steroids 499–506
Permanent phrenic nerve
paralysis
0% to 0.4% Monitor diaphragm during phrenic pacing, CMAP mon-
itoring, phrenic pacing to identify location and adjust lesion
location
CXR, sniff test Supportive care 9,11,156,347,367,446,457,478,479,487–490,507–528
Pulmonary vein stenosis o1% Avoid energy delivery within PV CT or MRI, V/Q wave scan Angioplasty, stent, surgery 9,11,313,316–335,457,529–531
Radiation injury o0.1% Minimize ﬂuoroscopy exposure, especially in obese and
repeat ablation patients, X-ray equipment
None Supportive care, rarely skin graft 513,532–550
Stiff left atrial syndrome o1.5% Limit extent of left atrial ablation Echocardiography, cardiac
catheterization
Diuretics 551–558
Stroke and TIA 0% to 2% Pre-, post-, and intraprocedure anticoagulation, catheter
and sheath management, TEE
Head CT or MRI, cerebral
angiography
Thrombolytic therapy, angioplasty 10–13,338,347,367,458,559–565
Vascular complications 0.2% to 1.5% Vascular access techniques, ultrasound-guided access,
anticoagulation management
Vascular ultrasound, CT scan Conservative treatment, surgical
repair, transfusion
338,347,371,373,374,380,458,511,566–575
AF ¼ atrial ﬁbrillation; CT ¼ computed tomography; MRI ¼ magnetic resonance imaging; TEE ¼ transesophageal electrocardiogram; RF ¼ radiofrequency; PTCA ¼ percutaneous transluminal coronary angioplasty; NA ¼ not
applicable; ECG ¼ electrocardiogram; NSAID ¼ nonsteroidal anti-inﬂammatory drug; CMAP ¼ compound motor action potentials; CXR ¼ chest X-ray; TIA ¼ transient ischemic attack.
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Table 10
Deﬁnitions for use when reporting outcomes of AF ablation and in designing clinical trials of catheter or surgical ablation of AF
Acute procedural success (pulmonary vein isolation) Acute procedural success is deﬁned as electrical isolation of all pulmonary veins. A minimal assess-
ment of electrical isolation of the PVs should consist of an assessment of entrance block. If other
methods are used to assess PVI, including exit block and/or the use of provocative agents such as
adenosine or isoproterenol, they should be prespeciﬁed. Furthermore, it is recommended that the
wait time used to screen for early recurrence of PV conduction once initial electrical isolation is
documented be speciﬁed in all prospective clinical trials.
Acute procedural success (not related by pulmonary vein
isolation)
Typically, this would apply to substrate ablation performed in addition to PVI for persistent AF.
Although some have proposed AF termination as a surrogate for acute procedural success, its rela-
tionship to long-term success is controversial. Complete elimination of the additional substrate
(localized rotational activation, scar region, non-PV trigger, or other target) and/or demonstration of
bidirectional conduction block across a linear ablation lesion would typically be considered the
appropriate endpoint.
One-year successn One-year success is deﬁned as freedom from AF/AFL/AT after removal from antiarrhythmic drug
therapy as assessed from the end of the 3month blanking period to 12 months following the ablation
procedure. Because cavotricuspid isthmus-dependent atrial ﬂutter is easily treated with cavotricuspid
isthmus ablation and is not an iatrogenic arrhythmia following a left atrial ablation procedure for AF, it
is reasonable for clinical trials to choose to prespecify that occurrence of isthmus-dependent atrial
ﬂutter, if conﬁrmed by entrainment maneuvers during electrophysiology testing, should not be
considered an ablation failure or primary effectiveness endpoint.
Alternative one-year success Although the one-year success deﬁnition provided above remains the recommended end point that
should be reported in all AF ablation trials, and the endpoint for which the objective performance
criteria listed below were developed, the Task Force recognizes that alternative deﬁnitions for success
can be used if the main goal of therapy in the study is to relieve AF-related symptoms and to improve
patient QOL. In particular, it is appropriate for clinical trials to deﬁne success as freedom from only
symptomatic AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed from the end of
the 3-month blanking period to 12 months following the ablation procedure if the main goal of
therapy in the study is to relieve AF-related symptoms and to improve patient QOL. However, because
symptoms of AF can resolve over time, and because studies have shown that asymptomatic AF
represents a greater proportion of all AF postablation than prior to ablation, clinical trials need to
continue to report freedom from both symptomatic and asymptomatic AF even if this alternative one
year success deﬁnition is used as the primary trial endpoint.
Clinical/partial successn It is reasonable for clinical trials to deﬁne and incorporate one or more secondary deﬁnitions of
success that can be referred to as "clinical success" or "partial success." If these alternative deﬁnitions
of success are included, they should be deﬁned prospectively. In prior Consensus Documents the Task
Force has proposed that clinical/partial success be deﬁned as a "75% or greater reduction in the
number of AF episodes, the duration of AF episodes, or the % time a patient is in AF as assessed with a
device capable of measuring AF burden in the presence or absence of previously ineffective antiar-
rhythmic drug therapy." Because there is no ﬁrm scientiﬁc basis for selecting the cutoff of 75% rather
than a different cutoff, this prior recommendation is provided only as an example of what future
clinical trials may choose to use as a deﬁnition of clinical/partial success.
Long-term successn Long-term success is deﬁned as freedom from AF/AFL/AT recurrences following the 3-month blanking
period through a minimum of 36-month follow-up from the date of the ablation procedure in the
absence of Class I and III antiarrhythmic drug therapy.
Recurrent AF/AFL/AT Recurrent AF/AFL/AT is deﬁned as AF/AFL/AT of at least 30 seconds' duration that is documented by an
ECG or device recording system and occurs following catheter ablation. Recurrent AF/AFL/AT may
occur within or following the post ablation blanking period. Recurrent AF/AFL/AT that occurs within
the postablation blanking period is not considered a failure of AF ablation.
Early recurrence of AF/AFL/AT Early recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation within three months of
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a "recurrence."
These are not counted toward the success rate if a blanking period is speciﬁed.
Recurrence of AF/AFL/AT Recurrence of AF/AFL/AT postablation is deﬁned as a recurrence of atrial ﬁbrillation more than
3 months following AF ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed
as a "recurrence."
Late recurrence of AF/AFL/AT Late recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation 12 months or more after AF
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a "recurrence."
Blanking period A blanking period of three months should be employed after ablation when reporting efﬁcacy out-
comes. Thus, early recurrences of AF/AFL/AT within the ﬁrst 3 months should not be classiﬁed as
treatment failure. If a blanking period of less than 3 months is chosen, it should be prespeciﬁed and
included in the Methods section.
Stroke screening A risk-based approach to determine the level of postablation stroke screening in clinical trials is
recommended by the Task Force. For ablation devices with a lower risk of stroke and for which a
stroke signal has not been reported, a minimum standardized neurological assessment of stroke
should be conducted by a physician at baseline and at hospital discharge or 24 hours after the pro-
cedure, whichever is later. If this neurological assessment demonstrates new abnormal ﬁndings, the
patient should have a formal neurological consult and examination with appropriate imaging (i.e.,
DW-MRI), used to conﬁrm any suspected diagnosis of stroke. For devices in which a higher risk of
stroke is suspected or revealed in prior trials, a formal neurological examination by a neurologist at
discharge or 24 hours after the procedure, whichever is later, is recommended. Appropriate imaging
should be obtained if this evaluation reveals a new neurological ﬁnding. In some studies in which
delayed stroke is a concern, repeat neurological screening at 30 days postablation might be
appropriate.
Detectable AF/AFL/AT Detectable AF is deﬁned as AF/AFL/AT of at least 30 seconds' duration when assessed with ECG
monitoring. If other monitoring systems are used, including implantable pacemakers, implantable
deﬁbrillators, and subcutaneous ECG monitoring devices, the deﬁnition of detectable AF needs to be
prespeciﬁed in the clinical trial based on the sensitivity and speciﬁcity of AF detection with the
particular device. We recommend that episodes of atrial ﬂutter and atrial tachycardia be included
within the broader deﬁnition of a detectable AF/AFL/AT episode.
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AF/AFL/AT burden It is reasonable for clinical trials to incorporate AF/AFL/AT burden as a secondary endpoint in a clinical
trial of AF ablation. In stating this it is recognized that there are no conclusive data that have validated
a rate of AF burden reduction as a predictor of patient beneﬁt (i.e. reduction in mortality and major
morbidities such as stroke, CHF, QOL, or hospitalization). If AF burden is included, it is important to
predeﬁne and standardize the monitoring technique that will be used to measure AF burden. Available
monitoring techniques have been discussed in this document. Should AF burden be selected as an
endpoint in a clinical trial, the chosen monitoring technique should be employed at least a month
prior to ablation to establish a baseline burden of AF.
Entrance block Entrance block is deﬁned as the absence, or if present, the dissociation, of electrical activity within the
PV antrum. Entrance block is most commonly evaluated using a circular multielectrode mapping
catheter positioned at the PV antrum. Entrance block can also be assessed using detailed point-by-
point mapping of the PV antrum guided by an electroanatomical mapping system. The particular
method used to assess entrance block should be speciﬁed in all clinical trials. Entrance block of the left
PVs should be assessed during distal coronary sinus or left atrial appendage pacing in order to dis-
tinguish far-ﬁeld atrial potentials from PV potentials. It is recommended that reassessment of
entrance block be performed a minimum of 20 minutes after initial establishment of PV isolation.
Procedural endpoints for AF ablation strategies not targeting the
PVs
Procedural endpoints for AF ablation strategies not targeting the PVs: The acute procedural endpoints
for ablation strategies not targeting the PVs vary depending on the speciﬁc ablation strategy and tool.
It is important that they be prespeciﬁed in all clinical trials. For example, if a linear ablation strategy is
used, documentation of bidirectional block across the ablation line must be shown. For ablation of
CFAEs, rotational activity, or non-PV triggers, the acute endpoint should at a minimum be elimination
of CFAEs, rotational activity, or non-PV triggers. Demonstration of AF slowing or termination is an
appropriate procedural endpoint, but it is not required as a procedural endpoint for AF ablation
strategies not targeting the PVs.
Esophageal temperature monitoring Esophageal temperature monitoring should be performed in all clinical trials of AF ablation. At a
minimum, a single thermocouple should be used. The location of the probe should be adjusted during
the procedure to reﬂect the location of energy delivery. Although this document does not provide
formal recommendations regarding the speciﬁc temperature or temperature change at which energy
delivery should be terminated, the Task Force does recommend that all trials prespecify temperature
guidelines for termination of energy delivery.
Enrolled subject An enrolled subject is deﬁned as a subject who has signed written informed consent to participate in
the trial in question.
Exit block Exit block is deﬁned as the inability to capture the atrium during pacing at multiple sites within the
PV antrum. Local capture of musculature within the pulmonary veins and/or antrum must be docu-
mented to be present to make this assessment. Exit block is demonstrated by a dissociated sponta-
neous pulmonary vein rhythm.
Nonablative strategies The optimal nonablative therapy for patients with persistent and long-standing persistent AF who are
randomized to the control arm of an AF ablation trial is a trial of a new Class I or III antiarrhythmic
agent or a higher dose of a previously failed antiarrhythmic agent. For patients with persistent or long-
standing persistent AF, performance of a direct-current cardioversion while taking the new or dose
adjusted antiarrhythmic agent should be performed, if restoration of sinus rhythm is not achieved
following initiation and/or dose adjustment of antiarrhythmic drug therapy. Failure of pharmacolo-
gical cardioversion alone is not adequate to declare this pharmacological strategy unsuccessful.
Noninducibility of atrial ﬁbrillation Noninducibility of atrial ﬁbrillation is deﬁned as the inability to induce atrial ﬁbrillation with a
standardized prespeciﬁed pharmacological or electrical stimulation protocol. The stimulation protocol
should be prespeciﬁed in the speciﬁc clinical trial. Common stimulation approaches include a high-
dose isoproterenol infusion protocol or repeated atrial burst pacing at progressively more rapid rates.
Patient populations for inclusion in clinical trials It is considered optimal for clinical trials to enroll patients with only one type of AF: paroxysmal,
persistent, or long-standing persistent. If more than one type of AF patient is enrolled, the results of
the trial should also be reported separately for each of the AF types. It is recognized that "early
persistent" AF responds to AF ablation to a similar degree as patients with paroxysmal AF and that the
response of patients with "late persistent AF" is more similar to that in those with long-standing
persistent AF.
Therapy consolidation period Following a 3-month blanking period, it is reasonable for clinical trials to incorporate an additional 1-
to 3-month therapy consolidation period. During this time, adjustment of antiarrhythmic medications
and/or cardioversion can be performed. Should a consolidation period be incorporated into a clinical
trial design, the minimum follow-up duration should be 9 months following the therapy consolidation
period. Performance of a repeat ablation procedure during the blanking or therapy consolidation
period would "reset" the endpoint of the study and trigger a new 3-month blanking period. Incor-
poration of a therapy consolidation period can be especially appropriate for clinical trials evaluating
the efﬁcacy of AF ablation for persistent or long-standing persistent AF. The challenge of this approach
is that it prolongs the overall study duration. Because of this concern regarding overall study duration,
we suggest that the therapy consolidation period be no more than 3 months in duration following the
3-month blanking period.
Recommendations regarding repeat ablation procedures It is recommended that all clinical trials report the single procedure efﬁcacy of catheter ablation.
Success is deﬁned as freedom from symptomatic or asymptomatic AF/AFL/AT of 30 seconds or longer
at 12 months postablation. Recurrences of AF/AFL/AT during the ﬁrst 3-month blanking period post-
AF ablation are not considered a failure. Performance of a repeat ablation procedure at any point after
the initial ablation procedure should be considered a failure of a single procedure strategy. It is
acceptable for a clinical trial to choose to prespecify and use a multiprocedure success rate as the
primary endpoint of a clinical trial. When a multiprocedure success is selected as the primary end-
point, efﬁcacy should be deﬁned as freedom from AF/ﬂutter or tachycardia at 12 months after the ﬁnal
ablation procedure. In the case of multiple procedures, repeat ablation procedures can be performed
at any time following the initial ablation procedure. All ablation procedures are subject to a 3-month
post blanking window, and all ablation trials should report efﬁcacy at 12 months after the ﬁnal
ablation procedure.
Cardioversion deﬁnitions
Failed electrical cardioversion
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Failed electrical cardioversion is deﬁned as the inability to restore sinus rhythm for 30 seconds or
longer following electrical cardioversion.
Successful electrical cardioversion Successful electrical cardioversion is deﬁned as the ability to restore sinus rhythm for at least 30
seconds following cardioversion.
Immediate AF recurrence postcardioversion Immediate AF recurrence postcardioversion is deﬁned as a recurrence of AF within 24 hours following
cardioversion. The most common time for an immediate recurrence is within 30–60 minutes
postcardioversion.
Early AF recurrence postcardioversion Early AF recurrence postcardioversion is deﬁned as a recurrence of AF within 30 days of a successful
cardioversion.
Late AF recurrence postcardioversion Late AF recurrence postcardioversion is deﬁned as recurrence of AF more than 30 days following a
successful cardioversion.
Surgical ablation deﬁnitions
Hybrid AF surgical ablation procedure Hybrid AF surgical ablation procedure is deﬁned as a joint AF ablation procedure performed by
electrophysiologists and cardiac surgeons either as part of a single "joint" procedure or performed as
two preplanned separate ablation procedures separated by no more than 6 months.
Surgical Maze ablation procedure Surgical Maze ablation procedure is deﬁned as a surgical ablation procedure for AF that includes, at a
minimum, the following components: (1) line from SVC to IVC; (2) line from IVC to the tricuspid valve;
(3) isolation of the PVs; (4) isolation of the posterior left atrium; (5) line from MV to the PVs;
(6) management of the LA appendage.
Stand-alone surgical AF ablation A surgical AF ablation procedure during which other cardiac surgical procedures are not performed
such as CABG, valve replacement, or valve repair.
Nomenclature for types of surgical AF ablation procedures We recommend that the term "Maze" procedure is appropriately used only to refer to the biatrial
lesion set of the Cox-Maze operation. It requires ablation of the RA and LA isthmuses. Less extensive
lesion sets should not be referred to as a "Maze" procedure, but rather as a surgical AF ablation
procedure. In general, surgical ablation procedures for AF can be grouped into three different groups:
(1) a full biatrial Cox-Maze procedure; (2) PVI alone; and (3) PVI combined with left atrial lesion sets.
Hybrid epicardial and endocardial AF ablation This term refers to a combined AF ablation procedure involving an off-pump minimally invasive
surgical AF ablation as well as a catheter-based AF ablation procedure designed to complement the
surgical lesion set. Hybrid ablation procedures may be performed in a single-procedure setting in a
hybrid operating room or a cardiac catheterization laboratory environment, or it can be staged. When
staged, it is most typical to have the patient undergo the minimally invasive surgical ablation pro-
cedure ﬁrst following by a catheter ablation procedure 1 to 3 months later. This latter approach is
referred to as a "staged Hybrid AF ablation procedure."
Minimum AF documentation, endpoints, TEE performance, and success rates in clinical trials
Minimum documentation for paroxysmal AF The minimum AF documentation requirement for paroxysmal AF is (1) physician's note indicating
recurrent self-terminating AF and (2) one electrocardiographically documented AF episode within
6 months prior to the ablation procedure.
Minimum documentation for persistent AF The minimum AF documentation requirement for persistent AF is (1) physician's note indicating
continuous AF 47 days but no more than 1 year and (2) a 24-hour Holter within 90 days of the
ablation procedure showing continuous AF.
Minimum documentation for early persistent AF The minimum AF documentation requirement for persistent AF is (1) physician's note indicating
continuous AF 47 days but no more than 3 months and (2) a 24-hour Holter showing continuous AF
within 90 days of the ablation procedure.
Minimum documentation for long-standing persistent AF The minimum AF documentation requirement for long-standing persistent AF is as follows: physi-
cian's note indicating at least 1 year of continuous AF plus a 24-hour Holter within 90 days of the
ablation procedure showing continuous AF. The performance of a successful cardioversion (sinus
rhythm 430 seconds) within 12 months of an ablation procedure with documented early recurrence
of AF within 30 days should not alter the classiﬁcation of AF as long-standing persistent.
Symptomatic AF/AFL/AT AF/AFL/AT that results in symptoms that are experienced by the patient. These symptoms can include
but are not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath. For patients
in continuous AF, reassessment of symptoms after restoration of sinus rhythm is recommended to
establish the relationship between symptoms and AF.
Documentation of AF-related symptoms Documentation by a physician evaluating the patient that the patient experiences symptoms that
could be attributable to AF. This does not require a time-stamped ECG, Holter, or event monitor at the
precise time of symptoms. For patients with persistent AF who initially report no symptoms, it is
reasonable to reassess symptom status after restoration of sinus rhythm with cardioversion.
Minimum effectiveness endpoint for patients with sympto-
matic and asymptomatic AF
The minimum effectiveness endpoint is freedom from symptomatic and asymptomatic episodes of AF/
AFL/AT recurrences at 12 months following ablation, free from antiarrhythmic drug therapy, and
including a prespeciﬁed blanking period.
Minimum chronic acceptable success rate: paroxysmal AF at
12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for paroxysmal AF at 12-month
follow-up is 50%.
Minimum chronic acceptable success rate: persistent AF at 12-
month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for persistent AF at 12-month
follow-up is 40%.
Minimum chronic acceptable success rate: long-standing
persistent AF at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial,
we recommend that the minimum chronic acceptable success rate for long-standing persistent AF at
12-month follow-up is 30%.
Minimum follow-up screening for paroxysmal AF recurrence For paroxysmal AF, the minimum follow-up screening should include (1) 12-lead ECG at each follow-
up visit; (2) 24-hour Holter at the end of the follow-up period (e.g., 12 months); and (3) event
recording with an event monitor regularly and when symptoms occur from the end of the 3-month
blanking period to the end of follow-up (e.g., 12 months).
Minimum follow-up screening for persistent or long-standing
AF recurrence
For persistent and long-standing persistent AF, the minimum follow-up screening should include
(1) 12-lead ECG at each follow-up visit; (2) 24-hour Holter every 6 months; and (3) symptom-driven
event monitoring.
Requirements for transesophageal echocardiogram It is recommended that the minimum requirement for performance of a TEE in a clinical trial should
be those requirements set forth in ACC/AHA/HRS 2014 Guidelines for AF Management pertaining to
anticoagulation at the time of cardioversion. Prior to undergoing an AF ablation procedure a TEE
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should be performed in all patients with AF of 448 hours' duration or of unknown duration if
adequate systemic anticoagulation has not been maintained for at least 3 weeks prior to AF ablation. If
a TEE is performed for this indication, it should be performed within 24 hours of the ablation
procedure.
AF ¼ atrial ﬁbrillation; DW-MRI ¼ diffusion-weighted magnetic resonance imaging; CHF ¼ congestive heart failure; QOL ¼ quality of life; ECG ¼ electrocardiogram; CABG
¼ coronary artery bypass grafting; PV ¼ pulmonary vein; SVC ¼ superior vena cava; IVC ¼ inferior vena cava; CFAE ¼ complex fractionated atrial electrogram; PVI ¼
pulmonary vein isolation; AFL ¼ atrial ﬂutter; AT ¼ atrial tachycardia; ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; HRS ¼ Heart Rhythm
Society.
n When reporting outcomes of AF ablation, the development of atrial tachycardia or atrial ﬂutter should be included in the broad deﬁnition of recurrence following AF
ablation. All studies should report freedom from AF, atrial tachycardia, and atrial ﬂutter. These endpoints can also be reported separately. All studies should also clearly
specify the type and frequency of ECG monitoring as well as the degree of compliance with the prespeciﬁed monitoring protocol.
Table 11
Quality-of-life scales, deﬁnitions, and strengths
Scale Deﬁnition/Details Strengths/Weaknesses
Short Form (36) Health Survey (SF36)38
(General)
Consists of 8 equally weighted, scaled scores in the following
sections: vitality, physical functioning, bodily pain, general
health perceptions, physical role functioning, emotional role
functioning, social role functioning, mental health. Each
section receives a scale score from 0 to 100.
Physical component summary (PCS) and mental component
summary (MCS) is an average of all the physically and
mentally relevant questions, respectively.
The Short Form (12) Health Survey (SF12) is a shorter ver-
sion of the SF-36, which uses just 12 questions and still
provides scores that can be compared with SF-36 norms,
especially for summary physical and mental functioning.
Gives more precision in measuring QOL than EQ-5D but can
be harder to transform into cost utility analysis.
Advantages: extensively validated in a number of disease and
health states. Might have more resolution than EQ-50 for AF
QOL.
Disadvantages: not speciﬁc for AF, so might not have reso-
lution to detect AF-speciﬁc changes in QOL.
EuroQol Five Dimensions Questionnaire
(EQ-5D)39
(General)
Two components: Health state description is measured in
ﬁve dimensions: mobility, self-care, usual activities, pain/
discomfort, anxiety/depression. Answers may be provided
on a three-level (3L) or ﬁve-level (5L) scale. In the Evaluation
section, respondents evaluate their overall health status
using a visual analogue scale (EQ-VAS). Results can easily be
converted to quality-adjusted life years for cost utility
analysis.
Advantages: extensively validated in a number of disease and
health states. Can easily be converted into quality-adjusted
life years for cost-effectiveness analysis.
Disadvantages: might not be speciﬁc enough to detect AF-
speciﬁc changes in QOL. Might be less speciﬁc than SF-36.
AF effect on Quality of Life Survey (AFEQT)
40 (AF speciﬁc)
20 questions: 4 targeting AF-related symptoms, 8 evaluating
daily function, and 6 assessing AF treatment concerns. Each
item scored on a 7-point Likert scale.
Advantages: brief, simple, very responsive to AF interven-
tions. Good internal validity and well validated against a
number of other global and AF-speciﬁc QOL scales. Used in
CABANA.
Disadvantages: validation in only two published studies
(approximately 219 patients).
Quality of Life Questionnaire for Patients
with AF
(AF-QoL)41
(AF speciﬁc)
18-item self-administered questionnaire with three
domains: psychological, physical, and sexual activity. Each
item scores on a 5-point Likert scale.
Advantages: brief, simple, responsive to AF interventions;
good internal validity; used in SARA trial.
Disadvantages: external validity compared only to SF-36;
formal validation in 1 study (approximately 400 patients).
Arrhythmia-Related Symptom Checklist
(SCL)42 (AF speciﬁc)
16 items covering AF symptom frequency and symptom
severity.
Advantages: most extensively validated in a number of
arrhythmia cohorts and clinical trials.
Disadvantages: time-consuming and uncertain generalizability.
Mayo AF Speciﬁc Symptom Inventory
(MAFSI)43 (AF speciﬁc)
10 items covering AF symptom frequency and severity.
Combination of 5- point and 3-point Likert scale responses.
Used in CABANA trial.
Advantages: validated in an AF ablation population and
responsive to ablation outcome; used in CABANA trial.
Disadvantages: external validity compared only to SF-36;
1 validation study (approximately 300 patients).
University of Toronto Atrial Fibrillation
Severity Scale (AFSS) (AF speciﬁc)44
10 items covering frequency, duration, and severity. 7-point
Likert scale responses.
Advantages: validated and reproducible; used in CTAF trial.
Disadvantages: time-consuming and uncertain generalizability.
Arrhythmia Speciﬁc Questionnaire in
Tachycardia and Arrhythmia (ASTA)45
(AF speciﬁc)
Records number of AF episodes and average episode dura-
tion during last 3 months. 8 symptoms and 2 disabling
symptoms are recorded with scores from 1–4 for each.
Advantages: validated in various arrhythmia groups; external
validity compared with SCL, EQ5D, and SF-36; used in
MANTRA-PAF; brief; simple.
Disadvantages: one validation study (approximately 300
patients).
European Heart Rhythm Association
(EHRA)46 (AF speciﬁc)
Like NYHA scale. I ¼ no symptoms, II ¼ mild symptoms not
affecting daily activity, III ¼ severe symptoms affecting daily
activity, and IV ¼ disabling symptoms terminating daily
activities.
Advantage: very simple, like NYHA.
Disadvantages: not used in studies and not well validated;
not very speciﬁc; unknown generalizability.
Canadian Cardiovascular Society Severity
of Atrial Fibrillation Scale (CCS-SAF)47
(AF speciﬁc)
Like NYHA scale. O ¼ asymptomatic, I ¼ AF symptoms have
minimal effect on patient's QOL, II ¼ AF symptoms have
minor effect on patient QOL, III ¼ symptoms have moderate
effect on patient QOL, IV¼ AF symptoms have severe effect
on patient QOL.
Advantages: very simple, like NYHA; validated against SF-36
and University of Toronto AFSS.
Disadvantages: poor correlation with subjective
AF burden; not very speciﬁc.
AF ¼ atrial ﬁbrillation; QOL ¼ quality of life; CABANA ¼ Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation; SARA ¼ Study of Ablation Versus
antiaRrhythmic Drugs in Persistent Atrial Fibrillation; CTAF ¼ Canadian Trial of Atrial Fibrillation; MANTRA-PAF ¼ Medical ANtiarrhythmic Treatment or Radiofrequency
Ablation in Paroxysmal Atrial Fibrillation; NYHA ¼ New York Heart Association; AFSS ¼ atrial ﬁbrillation severity scale.
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Non-AF recurrence–related endpoints for reporting in AF ablation trials
Stroke and bleeding endpoints Deﬁnitions/Details
Stroke (2014 ACC/AHA Key Data Elements) An acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular
injury as a result of hemorrhage or infarction. Symptoms or signs must persist Z24 hours, or if documented by
CT, MRI or autopsy, the duration of symptoms/signs may be less than 24 hours. Stroke may be classiﬁed as
ischemic (including hemorrhagic transformation of ischemic stroke), hemorrhagic, or undetermined. Stroke
disability measurement is typically performed using the modiﬁed Rankin Scale (mRS).
Transient ischemic attack (2014 ACC/AHA Key Data
Elements)
Transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia without
acute infarction and with signs and symptoms lasting less than 24 hours.
Major bleeding (ISTH deﬁnition) Fatal bleeding AND/OR symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal,
intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome AND/OR
bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or
more units of blood.
Clinically relevant nonmajor bleed (ISTH deﬁnition) An acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a
clinical response such that it leads to one of the following: hospital admission for bleeding; physician-guided
medical or surgical treatment for bleeding; change in antithrombotic therapy (including interruption or
discontinuation).
Minor bleeding (ISTH deﬁnition) All nonmajor bleeds. Minor bleeds are further divided into clinically relevant and not.
Incidence and discontinuation of oral anticoagulation The number of patients receiving oral anticoagulation and the type of oral anticoagulation should be docu-
mented at the end of follow-up. If patients have their oral anticoagulation discontinued, the number of patients
discontinuing, the timing of discontinuation, and the reasons for discontinuation of oral anticoagulation, as well
as the clinical characteristics and stroke risk proﬁle of the patients should be reported.
AF ¼ atrial ﬁbrillation; CT ¼ computed tomography; MRI ¼ magnetic resonance imaging.
Table 13
Advantages and disadvantages of AF-related endpoints in AF ablation trials
Endpoint Advantages Disadvantages Relevance and Comments
Freedom from AF/AFL/AT recur-
rence "gold standard" is 30
seconds
- Has been in use for many years
- Can be used to compare results of
new trials with historical trials
- Sets a high bar for AF elimination
- Can systematically underestimate the
efﬁcacy of AF ablation, particularly for
persistent AF, if 30-second cutoff is used
- Particularly well suited for paroxysmal AF
outcomes
- Reporting of cutoffs other than 30 seconds
encouraged as secondary endpoints to bet-
ter contextualize results
- May be reported as proportion of patients
free from arrhythmia or time to recurrence
Freedom from stroke-relevant AF/
AFL/AT-duration cutoff of 1 hour
- Useful for trials in which interest is
more for prognostic change con-
ferred by ablation rather than elim-
ination of all arrhythmias
- No consistent deﬁnition of what a
stroke-relevant duration of AF is: ranges
from 6 minutes to 24 hours in literature
- More than 1 hour could be a useful cutoff
based on results of 505 trial
- May be reported as proportion of patients
free from arrhythmia or time to recurrence
Freedom from AF/AFL/AT requiring
intervention (emergency visits,
cardioversion, urgent care visit,
reablation, etc.)
- Can provide an endpoint more rele-
vant to systemic costs of AF
recurrence
- Clinically relevant
- Will overestimate efﬁcacy of ablation by
ignoring shorter episodes not requiring
intervention that still might be impor-
tant to quality of life or stroke
- Determination of what is an "intervention"
must be prespeciﬁed in protocol and biases
mitigated to avoid over- or under-
intervention in the trial
Freedom from persistent AF/AFL/
AT-duration cutoff of 7 days
- Useful for trials assessing additional
substrate modiﬁcation in
persistent AF
- Can systematically overestimate the
efﬁcacy of AF ablation, particularly for
persistent AF
- Can require continuous monitoring to deﬁ-
nitively assess if episode is 47 days
Freedom from AF/AFL/AT on pre-
viously ineffective antiar-
rhythmic therapy
- If patient maintains sinus rhythm on
previously ineffective drug therapy,
this may be considered a clinically
relevant, successful outcome
- Will increase the success rate compared
with off-drug success
- May not be relevant to patients hoping
to discontinue drug therapy
- Postablation drug and dosage of drug
should be identical to preablation drug
and dosage
Signiﬁcant reduction in AF burden:
475% reduction from pre- to
postablation and/or total post-
ablation burden o12%
- Can be useful in persistent AF stu-
dies, but might not be suited for
early, paroxysmal AF studies
- Ideally requires continuous monitoring
using an implantable device
- No scientiﬁc basic exists showing that a
75% reduction in AF burden impacts
hard endpoints, including heart failure,
stroke, and mortality
- AF burden can be estimated by intermittent
monitoring and reporting of patient symp-
toms and recurrences like a "time in ther-
apeutic range" report for oral antic-
oagulation; see text
- Could also see 75% reduction in number and
duration of AF episodes
- Because there is no ﬁrm scientiﬁc basis for
selecting the cutoff of 75%, this prior
recommendation is provided only as an
example of what future clinical trials may
choose to use as a deﬁnition of clinical/
partial success
Prevention in AF progression: time
to ﬁrst episode of persistent AF
(47 days)
- Does not assume that total elimina-
tion of AF is required
- Well suited for paroxysmal or "early"
AF studies in which goal is to prevent
progression to persistent AF
- Prevention in progression might be
irrelevant for stroke or thromboembolic
outcomes
- Long follow-up time might be required
unless population is "enriched"
- Can ideally require continuous implan-
table monitoring
- Might be useful for speciﬁc populations
such as heart failure or hypertrophic cardi-
omyopathy, in which progression to per-
sistent AF can lead to increased
hospitalization
Regression of AF: reduction in
burden to a given threshold or
conversion of persistent to par-
oxysmal AF
- Does not assume that total elimina-
tion of AF is required
- Well suited for persistent "late" AF
studies in which goal is to regress to
- Regression endpoint will overestimate
efﬁcacy of AF ablation
- Might ideally require continuous
implantable monitoring
- Could be particularly useful for long-
standing persistent AF populations with
structural heart disease, heart failure, etc.
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Endpoint Advantages Disadvantages Relevance and Comments
paroxysmal AF, which might be
easier to control with drug therapy
- Patients will require ongoing drug
therapy
Acute AF termination during abla-
tion procedure
- Could provide indication of success-
ful modiﬁcation of substrate respon-
sible for maintaining AF, most rele-
vant to persistent or long-standing
persistent AF
- Limited studies have linked acute AF
termination to long-term success
- Relevance of acute AF termination has
not consistently been shown to correlate
to long-term success
- Endpoint might not be relevant to par-
oxysmal AF patients in whom AF might
terminate spontaneously
- Some studies employ administration of
intravenous or oral antiarrhythmics
during ablation that could cause spon-
taneous termination
- Studies consider termination as rever-
sion to sinus rhythm, whereas others
consider reversion to any regular tachy-
cardia as termination
- Intraprocedural administration of pre-
procedural oral antiarrhythmics or intra-
procedural intravenous antiarrhythmics are
discouraged
- If antiarrhythmics are used, their use and
dosage before and during the ablation
should be clearly documented
- Termination to sinus rhythm and termina-
tion to another regular tachycardia (AT or
AFL) should be separately reported
AF ¼ atrial ﬁbrillation; AFL ¼ atrial ﬂutter; AT ¼ atrial tachycardia.
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AF ablation? Does a team approach achieve better outcomes
than a "silo" approach?
2. Improving the safety of catheter ablation: As ablation extends to
more operators and less experienced operators, the statistical
occurrence of complications will increase. We need newer
techniques to minimize complications and institute standards
for operators to improve the reproducibility of ablation results
and safety proﬁles at a variety of centers worldwide.
3. How does catheter ablation affect mortality, stroke, and hospi-
talization in broad and selected patient populations receiving
catheter ablation for AF?
4. Management of patients who fail initial attempts at catheter
ablation: Should there be speciﬁc criteria for repeat ablations
(e.g., atrial size, body mass index)? Should patients be referred
for surgery for repeat ablation?
In order to address these and other important questions in the
ﬁeld of catheter and surgical AF ablation, we urge investigators to
create and participate in multisite collaborations and electro-
physiology research networks with involvement of senior and
junior investigators on the steering committees to push forward
the next phase of AF research. We also urge funding bodies to
support these important initiatives.Section 14: Conclusion
Catheter ablation of AF is a very commonly performed proce-
dure in hospitals throughout the world. This document providesan up-to-date review of the indications, techniques, and outcomes
of catheter and surgical ablation of AF. Areas for which a consensus
can be reached concerning AF ablation are identiﬁed, and a series
of consensus deﬁnitions have been developed for use in future
clinical trials of AF ablation. Also included within this document
are recommendations concerning indications for AF ablation,
technical performance of this procedure, and training. It is our
hope to improve patient care by providing a foundation for those
involved with care of patients with AF as well as those who per-
form AF ablation. It is recognized that this ﬁeld continues to evolve
rapidly and that this document will need to be updated. Successful
AF ablation programs optimally should consist of a cooperative
team of cardiologists, electrophysiologists, and surgeons to ensure
appropriate indications, procedure selection, and follow-up.Acknowledgments
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